IPSC Stock Forecast: Century Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Century Therapeutics, Inc. is $4.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 44 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Century Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (89): The shares have been drifting up relative to others.
Growth (13): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IPSC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IPSC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 May 2026 | Mizuho | Initiates | Outperform | $8.00 |
| 21 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Jan 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Nov 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 16 May 2025 | Chardan Capital | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Mar 2025 | Guggenheim | Reiterates | Buy | — |
| 24 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 21 Mar 2025 | Guggenheim | Maintains | Buy | — |
| 20 Mar 2025 | Piper Sandler | Maintains | Overweight | — |
| 22 Jan 2025 | Guggenheim | Reiterates | Buy | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Dec 2024 | Piper Sandler | Maintains | Overweight | — |
| 7 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 June 2024 | Piper Sandler | Maintains | Overweight | — |
| 4 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Apr 2024 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IPSC.
This page is one stock. Monday covers all of them.
IPSC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IPSC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Century Therapeutics, Inc. returned +137.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IPSC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.9×
- Price / book
- 1.0×
- EV / EBITDA
- —
Cheaper than 49% of US stocks
Cheaper than 71% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −9.6%
- Net margin
- —
Higher than 26% of US stocks
- Return on equity
- −51.2%
- Return on assets
- −25.5%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Century Therapeutics, Inc. has a market value of $211.6M and an enterprise value of $131.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$109.8M.
Free cash flow in the twelve months to 30 June 2026: −$88.1M.
Century Therapeutics, Inc. employs 78 people.
Data provided by Twelve Data
IPSC and its peers
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| IPSCCentury Therapeutics, Inc. | $211.6M | 44 |
| ALLOAllogene Therapeutics, Inc. | $207.9M | 45 |
| RCKTRocket Pharmaceuticals, Inc. | $211.0M | 36 |
| ARCTArcturus Therapeutics Holdings, Inc. | $211.7M | 74 |
| DTILPrecision BioSciences, Inc. | $204.3M | 81 |
| VNDAVanda Pharmaceuticals, Inc. | $203.6M | 72 |
| FTHFaeth Therapeutics, Inc. | $203.1M | 26 |
Take a look at IPSC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Century Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IPSC
What is the IPSC stock price forecast for 2026-2027?
The median 12-month analyst price target for Century Therapeutics, Inc. is $4.5, with estimates ranging from $2 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IPSC stock a buy right now?
Of the 5 analysts covering Century Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Century Therapeutics, Inc. 44 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IPSC?
As at 21 Nov 2026, Century Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (89 of 100).
Will IPSC stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $4.5, and Ticker Nerd's factor model ranks Century Therapeutics, Inc. 44 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IPSC stock forecast for 2030?
No analyst covering Century Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IPSC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $8 over the next 12 months.
How has IPSC stock performed over the past year?
Century Therapeutics, Inc. returned +137.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Century Therapeutics, Inc. do?
Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies.
About Century Therapeutics, Inc.
Century Therapeutics Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer, autoimmune diseases, and other immune-mediated conditions. The company uses induced pluripotent stem cell technology to create off-the-shelf immune cell products, including natural killer and T cell therapies designed to target solid tumors and hematological malignancies. Its current pipeline also includes programs in type 1 diabetes and other autoimmune applications, reflecting a broader effort to apply engineered cell therapy platforms across multiple disease areas. Century Therapeutics combines stem cell derivation, gene editing, and immune-evasion technologies to support scalable manufacturing and differentiated product development. Headquartered in Philadelphia, Pennsylvania, Century Therapeutics operates in the advanced biotechnology segment of the healthcare market, where it develops next-generation cellular medicines intended for clinical use.
CEO Dr. Brent Pfeiffenberger M.B.A., Pharm.D. · 78 employees · United States · https://www.centurytx.com